Palomino Laboratories Inc Financials
This page shows Palomino Laboratories Inc (PALX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Palomino Laboratories Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Palomino Laboratories Inc carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 25.07, Palomino Laboratories Inc holds $25.07 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Palomino Laboratories Inc generates a -39.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Palomino Laboratories Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Palomino Laboratories Inc generates $0.41 in operating cash flow (-$1.3M OCF vs -$3.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Palomino Laboratories Inc reported -$3.2M in net income in fiscal year 2025. This represents a decrease of 19428.3% from the prior year.
Palomino Laboratories Inc earned $-0.47 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 4181.8% from the prior year.
Cash & Balance Sheet
Palomino Laboratories Inc held $8.1M in cash against $0 in long-term debt as of fiscal year 2025.
Palomino Laboratories Inc had 19M shares outstanding in fiscal year 2025. This represents an increase of 317.1% from the prior year.
Margins & Returns
Palomino Laboratories Inc's ROE was -39.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
PALX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $1.6M+4414.8% | $36K-33.6% | $54K | N/A | $1K | N/A | N/A |
| Operating Income | N/A | -$1.6M-4414.8% | -$36K+33.6% | -$54K | N/A | -$1K | N/A | N/A |
| Interest Expense | N/A | N/A | $8K-40.9% | $14K | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$1.8M-568.6% | $389K | N/A | N/A | N/A | $346+240.1% | -$247 |
| EPS (Diluted) | N/A | $-0.54 | $-0.01+25.0% | $-0.01 | N/A | $0.00+100.0% | $-0.01+40.0% | $-0.01 |
PALX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.4M+1.5% | $8.3M+369.8% | $1.8M+9611.6% | $18K-86.8% | $138K+42796.0% | $3220.0% | $322-15.3% | $380 |
| Current Assets | $8.4M | N/A | $1.7M+9474.3% | $18K-86.8% | $138K+42796.0% | $3220.0% | $322-15.3% | $380 |
| Cash & Equivalents | $8.1M+2.8% | $7.9M+358.1% | $1.7M+9360.2% | $18K-86.5% | $135K | N/A | N/A | $380 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $336K-66.3% | $999K-54.9% | $2.2M+119.5% | $1.0M+545.6% | $156K+1705.3% | $9K+271.7% | $2K-87.5% | $19K |
| Current Liabilities | $336K-66.3% | $999K+665.4% | $131K-61.3% | $337K+5140.1% | $6K | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.1M+10.7% | $7.3M+1735.3% | -$447K+54.9% | -$992K-5317.1% | -$18K-119.4% | -$8K-315.3% | -$2K+89.0% | -$18K |
| Retained Earnings | -$3.2M-30.4% | -$2.4M-297.1% | -$614K-92.4% | -$319K-1638.4% | -$18K+91.7% | -$222K-13.9% | -$195K-19.5% | -$163K |
PALX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$894K-188.7% | -$310K-342.1% | -$70K-539.3% | -$11K-92.3% | -$6K-5056.5% | $115 | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.1M-82.7% | $6.5M | N/A | N/A | $145K | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PALX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -24.9% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -21.9%-44.0pp | 22.0% | N/A | N/A | N/A | 107.5%+172.4pp | -65.0% |
| Current Ratio | 25.07 | N/A | 13.37+13.3 | 0.05-21.4 | 21.48 | N/A | N/A | N/A |
| Debt-to-Equity | 0.04-0.1 | 0.14+5.1 | -4.96-3.9 | -1.02+7.5 | -8.55-7.5 | -1.04+0.1 | -1.16-0.1 | -1.02 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
Is Palomino Laboratories Inc profitable?
No, Palomino Laboratories Inc (PALX) reported a net income of -$3.2M in fiscal year 2025.
What is Palomino Laboratories Inc's return on equity (ROE)?
Palomino Laboratories Inc (PALX) has a return on equity of -39.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Palomino Laboratories Inc's operating cash flow?
Palomino Laboratories Inc (PALX) generated -$1.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Palomino Laboratories Inc's total assets?
Palomino Laboratories Inc (PALX) had $8.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Palomino Laboratories Inc's current ratio?
Palomino Laboratories Inc (PALX) had a current ratio of 25.07 as of fiscal year 2025, which is generally considered healthy.
What is Palomino Laboratories Inc's debt-to-equity ratio?
Palomino Laboratories Inc (PALX) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Palomino Laboratories Inc's return on assets (ROA)?
Palomino Laboratories Inc (PALX) had a return on assets of -37.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Palomino Laboratories Inc's cash runway?
Based on fiscal year 2025 data, Palomino Laboratories Inc (PALX) had $8.1M in cash against an annual operating cash burn of $1.3M. This gives an estimated cash runway of approximately 76 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Palomino Laboratories Inc's Piotroski F-Score?
Palomino Laboratories Inc (PALX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Palomino Laboratories Inc's earnings high quality?
Palomino Laboratories Inc (PALX) has an earnings quality ratio of 0.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Palomino Laboratories Inc?
Palomino Laboratories Inc (PALX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.